EGFR L702fs

CI-VAR-00002384Explore in graph →CIViC 5413

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
EGFR E701fs AND EGFR L702fs	Osimertinib Mesylate	Predictive	C	Supports Sensitivity Response	3	submitted	EID12865 Two uncommon EGFR frameshift deletions (E701fs and L702fs; VAFs of 32.8% and 21.5%, respectively) were identified by NGS in a patient with NSCLC. The patient was enrolled in the OCELOT clinical trial … (full text at CIViC) PMID 41590375 · Wong et al., 2026 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.